High-Risk Rhabdomyosarcoma
This phase III trial compares the effect of vinorelbine with vincristine, dactinomycin, and cyclophosphamide (VAC) followed by vinorelbine and cyclophosphamide versus VAC followed by vinorelbine and cyclophosphamide for the treatment of high risk rhabdomyosarcoma. Chemotherapy drugs, such as v...
About
Protocol Description
A Randomized Phase 3 Trial of Vinorelbine, Dactinomycin, and Cyclophosphamide (VINO-AC) Plus Maintenance Chemotherapy with Vinorelbine and Oral Cyclophosphamide (VINO-CPO) vs Vincristine, Dactinomycin and Cyclophosphamide (VAC) plus VINO-CPO Maintenance in Patients with High Risk Rhabdomyosarcoma (HR-RMS)
COG# ARST2031
Eligibility Criteria
Inclusion Criteria
- Patients with newly diagnosed rhabdomyosarcoma of any subtype, except adult-type pleomorphic
- Adequate renal function as defined by the protocol
- Adequate liver function as defined by the protocol
Exclusion Criteria
- Rhabdomyosarcoma that is considered a second malignancy
- Patients with central nervous system involvement of RMS as defined by the protocol
- Patients who have received any chemotherapy (excluding steroids) and/or radiation therapy for rhabdomyosarcoma prior to enrollment.
- Pregnant or lactating individuals
Primary Investigator
Dr. Glenn Edwards is the Section Chief of Pediatric Hematology/Oncology, as well as the Children's Oncology Group's Principal Investigator for Carilion Clinic, and has over 30 years of clinical experience. He is board certified by the American Board of Pediatrics in Pediatrics and Pediatric Hematology/Oncology. He completed his Fellowship at Walter Reed Army Medical Center and completed his Internship and Residency at Tripler Army Medical Center.
Contact Information
Wendy McCarty, CCRP
Clinical Research Coordinator II
